Ambulatory Peritoneal Dialysis

ISBN-13: 9781461595571 / Angielski / Miękka / 2012 / 356 str.

M. M. Avram; C. Giordano

Opis

The Fourth International Congress of Peritoneal Dialysis was held in Venice, Italy, June 29 to July 2, 1987. By this time peritoneal dialysis had emerged as a treatment for a substantial fraction of patients with end-stage renal disease and countless numbers of patients with acute renal failure. This treatment is now practiced worldwide and is the life-sustaining treatment for about 40,000 patients with chronic renal failure, representing 15 to 20% of dialysis therapy in about 1000 centers. It is not surprising, therefore, that the number of health professionals engaged in the investigation and the application of the treatment has also grown exponen tially. The First International Symposium on Peritoneal Dialysis, organized by Dr. A. Treviiio-Be cerra in Chapala, Mexico, in 1978, brought together a group of pioneers when continuous ambulatory peritoneal dialysis was in its infancy. In 1981, Dr. G. M. Gahl chaired the Second Symposium, in West Berlin, when the technique and professional interest were growing con siderably. By 1984, when Dr. 1. F. Winchester and I organized the Third Symposium, the pre sented papers exceeded 100 and there were about 1000 attendees. At that time, it was deemed appropriate to form a more organized group and the International Society for Peritoneal Dialy sis was founded. One of the first actions of the Society was to choose from among several applicants Dr."

Spis treści

I. Status of the Art.- 1. The Role of Cholesterol and Lipids in the Atherogenicity of Continuous Ambulatory Peritoneal Dialysis Patients: Update 1990.- 2. Erythropoietin in Continuous Ambulatory Peritoneal Dialysis Patients, 1990: Benefits of the Subcutaneous Route in the First U. S. Experience.- 3. Solving the Major Problems of Continuous Ambulatory Peritoneal Dialysis.- 4. Functional and Histological Changes of Peritoneal Membrane in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 5. Where Are We Going?.- II. Physiology, Pharmacology, and Morphology.- 6. Peritoneal Ultrafiltration: Less Efficient with Prolonged Dwell or Excessive Dialysate Dextrose.- 7. Neostigmine Increases Net Ultrafiltration and Solute Clearances in Peritoneal Dialysis by Reducing Lymphatic Absorption.- 8. Phosphatidylcholine Increases Ultrafiltration in Continuous Ambulatory Peritioneal Dialysis Patients.- 9. Effect of Cationic Molecules on the Permeability of the Mesothelium in Vitro.- 10. Phosphatidylcholine: A Physiological Modulator of the Peritoneal Membrane.- 11. Ultrafiltration Loss in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Intraperitoneal Therapy with Calcium Antagonists.- 12. A Chemoattractant in Peritoneal Effluent from Continuous Ambulatory Peritoneal Dialysis Patients.- 13. The Isolation and Culture of Human Mesothelial Cells: Characterization of Cyclooxygenase Products.- 14. Beta-Blockers Induce Functional Changes That Potentially Injure the Peritoneum in Continuous Ambulatory Peritoneal Dialysis Patients.- 15. Loss of Mesothelial and Microvascular Fixed Anionic Charges during Murine Experimentally Induced Septic Peritonitis.- 16. Role of Blood Osmolality in the Regulation of Vasopressin Secretion in Continuous Ambulatory Peritoneal Dialysis Patients.- 17. Lymphatic Absorption in Continuous Ambulatory Peritoneal Dialysis Patients with Normal and High Transperitoneal Glucose Transport.- 18. The Kinetics of Ultrafiltration during Peritoneal Dialysis in Rats: The Role of Lymphatics.- 19. Dihydroergotamine Lowers Peritoneal Transfer Rates: A Hypovolemic Transport Decrease.- 20. Ultrafiltration Patterns of Dextran and Hydroxyethylstarch during Long-Dwell Peritoneal Dialysis Exchanges in Nonuremic Rats.- 21. Peritoneal Clearances, Ultrafiltration, and Diuresis in Long-Term Continuous Ambulatory Peritoneal Dialysis.- 22. Effect of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis on the Transport of Inhibitory Factors of Lymphocyte Proliferation Present in Uremic Serum.- 23. Methotrexate Influences Peritoneal Permeability.- 24. High Doses of Intraperitoneal Furosemide in Long-Dwell Exchange.- 25. Calcium Peritoneal Mass Transfer in Continuous Ambulatory Peritoneal Dialysis.- 26. Structural Changes in Peritoneal Vessels during Continuous Ambulatory Peritoneal Dialysis: A Model for the Study of Diabetic Microangiopathy.- 27. Mesothelial Hyperplasia after Chronic Intraperitoneal Fluid Administration: A Light Microscopy Study in the Rat.- 28. Mitogenic Effect of the Peritoneal Effluent on Mice Fibroblast Cultures in Continuous Ambulatory Peritoneal Dialysis Patients.- 29. Oxygen Metabolism of Peritoneal Phagocytes.- III. Nutrition Metabolism.- 30. The Nutritional Status of Long-Term CAPD Patients.- 31. Renal Osteodystrophy: Bone Mineral Density Loss and Recovery with Treatment.- 32. Bone Mineralization Defect in Continuous Ambulatory Peritoneal Dialysis Patients.- 33. Faster Energy Turnover in Peritoneal Dialysis.- IV. Technology.- 34. One-Year Experience with Swan-Neck Missouri 2 Catheter.- 35. Thallium 201 Myocardial Imaging in Continuous Ambulatory Peritoneal Dialysis Patients at High Risk of Coronary Artery Disease.- 36. Tidal Peritoneal Dialysis.- 37. Absorption of Inulin and High-Molecular-Weight Gelatin Isocyanate Solutions from Peritoneal Cavity of Rats.- 38. Technical Developments in Continuous Ambulatory Peritoneal Dialysis: Summary of Personal Experiences.- 39. The Use of Hyposmolar Glucose Polymer Solution in Continuous Ambulatory Peritoneal Dialysis: A Seven-Day Study.- 40. Loss of Ultrafiltration Capacity: Role of Plasticizers.- 41. Chronic Peritoneal Dialysis Using Curled Catheters.- V. Peritonitis.- 42. Immune Defense and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 43. Peritoneal Macrophages of Patients on Continuous Ambulatory Peritoneal Dialysis Show Alterations in Sensitivity and Secretion of Prostaglandins during Peritonitis.- 44. Interferon Abnormalities and Peritonitis in Continuous Ambulatory Peritoneal Dialysis.- 45. Association of Staphylococcus aureus Nasal Carriage with Staphylococcus aureus Catheter Exit-Site Infections.- 46. Survival and Growth of Staphylococcus epidermidis within Phagocytes in Relation to Recurrent Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 47. Does Viral Infection Predispose to Peritonitis in Continuous Ambulatory Peritoneal Dialysis?.- 48. Peritonitis: The Most Serious Complication of Continuous Ambulatory Peritoneal Dialysis: Results of a Multi-Center Study.- 49. Generation and Release of Eicosanoids and Proteolytic Enzymes by Human Peritoneal Macrophages in Response to Staphylococcus epidermidis and the Calcium Ionophore A23187.- 50. Humoral and Cellular Host-Defense Factors and Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients.- 51. Continuous Ambulatory Peritoneal Dialysis Host Defenses and Staphylococcus aureus: Role of Opsonins, Fibronectin, Fibrinogen, and Fibrin.- 52. Long-Term Experience with the Y-Connector in Peritonitis Prevention in Continuous Ambulatory Peritoneal Dialysis Patients.- 53. Inhibition of Binding of Escherichia coli to Human Peritoneal Macrophages by Peritoneal Effluent from Patients on Peritoneal Dialysis.- 54. Use of Exudate Smears for Diagnosis of Peritoneal Catheter Exit-Site Infection.- 55. Early Bacteriological Diagnosis of Continuous Ambulatory Peritoneal Dialysis Peritonitis with the Use of a Cy to centrifuge.- VI. Clinical Experience.- 56. USA CAPD Registry: 1987 Report Highlights.- 57. Multi-Center Study of Outcome of Continuous Ambulatory Peritoneal Dialysis and Hemodialysis Patients: A 4-Year Analysis.- 58. Wilkinson Peritoneal Membrane Function in Myeloma.- 59. Risk Factors and Outcome of Diabetics on Continuous Ambulatory Peritoneal Dialysis.- 60. Survival of the “Ideal” Continuous Ambulatory Peritoneal Dialysis Patient.- 61. Efficacy of Hepatitis B Vaccine in Continuous Ambulatory Peritoneal Dialysis Patients Is Influenced by Blood Transfusion.- 62. Stable Continuous Ambulatory Peritoneal Dialysis Patients Assess the Suitability of New Candidates.- 63. Individualization of Exchange Volume to Optimize Continuous Ambulatory Peritoneal Dialysis.- 64. Postural Hypotension with Glucose Ingestion in Patients on Continuous Ambulatory Peritoneal Dialysis.- 65. Impact of Increasing Intraperitoneal Volume on Left Ventricular Function in Continuous Ambulatory Peritoneal Dialysis Patients.- 66. Continuous Cycling Peritoneal Dialysis: Wet Is Better Than Dry.- 67. Comparative Evaluation of Hemodialysis and Continuous Ambulatory Peritoneal Dialysis: A Multi-Center Study.- 68. Continuous Ambulatory Peritoneal Dialysis for the AIDS Patient.- 69. Comparative Study of Muzolimine and Furosemide in Continuous Ambulatory Peritoneal Dialysis Patients.- 70. Successful Joint Care of Continuous Ambulatory Peritoneal Dialysis Patients with Two District General Hospitals.- 71. The Benefits of Long-Life Tubing in Continuous Ambulatory Peritoneal Dialysis.- 72. Effect of Protein or Amino Acid Supplementation on the Nutritional Status of Patients on Continuous Ambulatory Peritoneal Dialysis.- 73. New Strategy following Peritoneal Catheter Implantation in Continuous Ambulatory Peritoneal Dialysis.- 74. Treatment of Refractory Congestive Heart Failure by Continuous Ambulatory Peritoneal Dialysis.- 75. Vitamin Deficiencies in Continuous Ambulatory Peritoneal Dialysis Patients: Effects of Supplementation.- 76. Leakage of Dialysate across the Diaphragm.- 77. Continuous Ambulatory Peritoneal Dialysis - An Adequate Therapy in Developing Countries.- VII. Experience in Infants and Children.- 78. Acute Peritoneal Dialysis in Premature and Newborn Infants.- 79. Peritoneal Dialysis in Acute Renal Failure in the Neonate: Limits and Complications.- 80. The Optimal Dialysis Regimen for Children Undergoing Different Continuous Cycling Peritoneal Dialysis Protocols.- 81. Intracellular Amino Acids in Children on Continuous Ambulatory Peritoneal Dialysis.- 82. Efficiency of High-Volume Continuous Ambulatory Peritoneal Dialysis in Children.- 83. Outpatient Cycler Peritoneal Dialysis for Home Failure, Hemodialysis Failure, AV Access Failure, and Cardiovascular Instability.- Contributors.